Natural Compounds with Anti-BACE1 Activity as Promising Therapeutic Drugs for Treating Alzheimer’s Disease

Authors
Mehjabeen Naushad1*, Siva Sundara Kumar Durairajan1*, Amal Kanti Bera2, Sanjib Senapati2, Min Li3

Affiliations
1 Department of Microbiology, School of Life Sciences, Central University of Tamil Nadu, Tiruvarur, India
2 Department of Biotechnology, Indian Institute of Technology Madras, Chennai, India
3 Neuroscience Research Laboratory, Mr. & Mrs. Ko Chi-Ming Centre for Parkinson’s Disease Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China

Key words
Alzheimer’s disease, BACE1, BACE1 inhibitors, flavonoids, phenolics, alkaloids, terpenes

received April 8, 2019
revised September 24, 2019
accepted September 26, 2019

ABSTRACT
Alzheimer’s disease is a neurodegenerative disease that leads to irreversible neuronal damage. Senile plaques, composed of amyloid beta peptide, is the principal abnormal characteristic of the disease. Among the factors involved, the secretase enzymes, namely, α secretase, beta-site amyloid precursor protein-cleaving enzyme, β secretase, and γ secretase, hold consequential importance. Beta-site amyloid precursor protein-cleaving enzyme 1 is considered to be the rate-limiting factor in the production of amyloid beta peptide. Research supporting the concept of inhibition of beta-site amyloid precursor protein-cleaving enzyme activity as one of the effective therapeutic targets in the mitigation of Alzheimer’s disease is well accepted. The identification of natural compounds, such as β-amyloid precursor protein-selective beta-site amyloid precursor protein-cleaving enzyme inhibitors, and the idea of compartmentalisation of the beta-site amyloid precursor protein-cleaving enzyme 1 action have caused a dire need to closely examine the natural compounds and their effectiveness in the disease mitigation. Many natural compounds have been reported to effectively modulate beta-site amyloid precursor protein-cleaving enzyme 1. At lower doses, compounds like 2,2’,4’-trihydroxychalcone acid, quercetin, and myricetin have been shown to effectively reduce beta-site amyloid precursor protein-cleaving enzyme 1 activity. The currently used five drugs that are marketed and used for the management of Alzheimer’s disease have an increased risk of toxicity and restricted therapeutic efficiency, hence, the search for new anti-Alzheimer’s disease drugs is of primary concern. A variety of natural compounds having pure pharmacological moieties showing multitargeting activity and others exhibiting specific beta-site amyloid precursor protein-cleaving enzyme 1 inhibition as discussed below have superior biosafety. Many of these compounds, which are isolated from medicinal herbs and marine flora, have been long used for the treatment of various ailments since ancient times in the Chinese and Ayurvedic medical systems. The aim of this article is to review the available data on the selected natural compounds, giving emphasis to the inhibition of beta-site amyloid precursor protein-cleaving enzyme 1 activity as a mode of Alzheimer’s disease treatment.

* These two authors contributed equally to this work.
Introduction

Alzheimer’s disease (AD) is a prevalent neurodegenerative pathology that is currently incurable [1]. Patients suffering from the disease are characterised by reduced cognitive function, progressive deterioration of the memory and neuronal damage, and changes in mood and behaviour [2]. Living with this disease can be debilitating and ultimately fatal. The presence of amyloid plaques (composed mainly of Aβ peptides) and neurofibrillary tangles (aggregates of hyperphosphorylated tau protein) is the main pathological characteristic of AD [3]. This is accompanied by microglial proliferation, neuropil threads, and associated astroglisis [4]. These pathological processes lead to the deterioration of the brain and its activities.

Sequential processing of the β-amyloid precursor protein (βAPP) by β secretase and γ secretase leads to the formation of the Aβ peptides [5]. The γ secretase cleaves C99 after the action of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1), leading to the formation of Aβ40 and Aβ42 in most cases [6]. β Secretase or BACE1 also known as memapsin 2, and Asp 2) holds one of the pivotal roles in AD disease pathogenesis as its protein levels and/or enzyme activity are observed to be significantly elevated in the AD brain compared to the slight elevation seen in the normal aging brain [7–9]. Hence, BACE1 is of specific interest as a drug target since its inhibition is considered a potential treatment, if not the cure. Similar to BACE1, BACE2 is a type I transmembrane protein and is a close homologue [10, 11]. BACE2 has been reported to cleave BAPP like BACE1, but the fragments produced have so far not been observed in senile plaques. Hence, its role in AD is questionable [11]. BACE2 is expressed highly in the peripheral tissues and in oligodendrocytes, astrocytes, and neuronal subsets [12], whereas BACE1 is highly concentrated only in the brain [10]. BACE1 is considered to be the rate-limiting factor involved in the formation of Aβ, and as such is a suitable target for drugs [13]. A detailed illustration of the BAPP processing by the secretases is depicted in Fig. 1.

Inhibition of BACE1 activity can be an effective therapeutic target for treating AD. Complete BACE1 inhibition was considered to be desirable after Roberds et al. and other independent studies reported that BACE1−/− mice failed to exhibit excessive Aβ deposition. Luo et al. also evidenced that BACE1 knockout fully prevents Aβ production while displaying a normal phenotype in mice [14, 15]. This gave rise to the idea that therapeutic inhibition BACE1 in humans, similar to BACE1−/−null mice, may be free of mechanism-based toxicity and thus an effective method in Alzheimer’s disease treatment. These analyses boosted the drug discoveries targeting complete BACE1 inhibition and many clinical trials which resulted in mild cognitive impairment. This leads to a need for further research and subsequent studies on complete BACE1 inhibition that found BACE1-null mice showed increased instances of seizures, schizophrenia-like phenotypes, demelination, axonal misguidance, and high offspring mortality rates in contrast to BACE1−/− mice (i.e., heterozygous mice with a genetically decreased level of BACE1). BACE1−/− mice failed to exhibit any side effects and phenotypic changes but showed potential Aβ reduction. Recent studies have shown that the A673T mutation of APP impairs cleavage by BACE1, resulting in protection against AD, thus further supporting BACE1 inhibition [16]. From the prior studies conducted [14–16] and the critical role played in amyloidogenic processing, BACE1 can thus be considered a probable target. Four therapeutic agents approved by the FDA (donepezil, rivastigmine, galantamine, and memantine) are currently being used to mitigate AD symptoms, but these drugs have not been able to prevent or reverse disease progression [17, 18]. As of 2018, 112 anti-AD agents are under investigation. Approximately 27% of these agents now in phase III clinical trials and ~ 5% in phase II clinical trials are BACE1 inhibitors [19]. As of 2019, the BACE1 inhibitors LY-3314814, MK-8931 (verubecestat), and LY-3202626 have been dropped from clinical trials. Some of BACE1 inhibitors like elenbecestat is progressing through the clinical trials [20, 21]. Every year several drugs are being developed to treat AD in hopes of satisfactory results, but most of them fail at the preclinical stage, even before entering clinical trials. There are different approaches for targeting BACE1, like inhibition of activity and suppression of BACE1 expression [22, 23]. As of 2019, less than 2% of the drugs in studies act by inhibition of BACE1 activity. Inhibition of BACE1 by natural products has rendered promising results in AD therapeutics as exemplified by flavonoids (galangin, myricetin, baicalein), alkaloids (berberine), terpenes, etc., which have shown BACE1 inhibition. These compounds show significant potential to act as therapeutic drugs. Further efficient strategies for inhibiting BACE1 activity is required in order to reduce the side effects caused by biological functions due to its long-term use [24].

The C99 cleavage can be impaired without interfering with multifunctional neuregulin 1 processing, which is a potential substrate of BACE1. This, combined with the possibility of compartmentalisation of the target, specifically targeting BACE1 inhibitors to endosomal compartments, preventing action on non-amyloid substrates [25], has paved the future for the development of a promising BACE1-based anti-AD therapeutic approach. The identification of further BAPP-selective natural BACE1 inhibitors could be advantageous, as this would prevent the secondary adverse effects due to cleavage of other substrates supporting some important physiological functions. The comprehension of safety profiles of many natural compounds showing potential BACE1 inhibition is already well understood due to its long-term use in traditional Chinese medicine (TCM) and Ayurvedic medicine. Some of the natural compounds that are widely used in traditional medicinal care with an emphasis on flavonoids, phenolic compounds, tannins, alkaloids, chalcones, and terpenes exhibit effective action by the inhibition of BACE1 activity at low concentrations are discussed below.

Search Strategy

A systemic search was carried out for literature in electronic databases, including PubMed, Scopus, Embase, Web of Science, Science Direct, and Google Scholar and were screened for natural compounds that exhibited potential BACE1 activity inhibition. In vivo, in vitro, and clinical evidence that assessed the therapeutic and preventive potential of natural compounds against the BACE1 enzyme involved in the production of Aβ, which is a major component of amyloid plaques and neurofibrillary tangles, were col-

Naushad M et al. Natural Compounds with... Planta Med 2019; 85: 1316–1325
lected. Relevant articles where searched to obtain natural BACE1 activity inhibitors for the mitigation of AD and its symptoms. The following key words were used to obtain significant data about the topic: Alzheimer’s disease, BACE1, natural compounds, BACE1 activity, and BACE1 inhibitors. The articles focusing on plant extracts or modified compound derivatives showing BACE1 inhibition were excluded in the study. Only full length articles available in the English language were reviewed.

Flavonoids Having Potential Anti-beta-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Activity

Descamps et al. [26] identified two bioflavonoids, rutin (1) (found in *Fagopyrum esculentum* Moench) and galangin (2) (found in *Alpinia officinarum* Hance), which have the ability to impair BACE1 cleavage by acting as βAPP-selective BACE1 inhibitors. Galangin in cell culture studies and AD transgenic mice studies (J20 mice) conducted (at dosages of 50 µM and 40 mg/kg, respectively) showed inhibition of BACE-dependent βAPP nuclear signalling, without affecting neuregulin. Hence, these commonly used nutritional supplement showed a novel mechanism to modulate βAPP processing even at lower concentrations, avoiding potential toxicity caused by direct inhibition of BACE1.

Baicalein (3) (5,6,7-trihydroxy-2-phenyl-chromen-4-one) is a flavone isolated from the roots of *Scutellaria baicalensis* Georgi. It is used in TCM and known to have potent antioxidant and free radical scavenging properties [27]. Recently, it gained attention due to its ability to act against neurodegenerative diseases [28, 29]. Baicalein (3) has been shown to have more potent anti-BACE1 activity when compared with other flavonoid compounds like luteolin and quercetin, with an IC50 value of about 10 µM [30]. Baicalein (3) has been shown to inhibit BACE1 activity as well as Aβ oligomerisation and fibrillation, and prevents Aβ-induced toxicity in PC12 cells along with the disaggregation of preformed Aβ amyloid fibrils [31]. The ability of the compound to cross the BBB is found to be negatively correlated with dose [31]. Gu et al. [32] suggest that the long-term oral administration of baicalein (3) leads to the reduction in BACE1 protein levels. Durairajan et al. [33] reported that prolonged treatment of baicalein led to enhanced Aβ deposition in both N2a-Swedish APP cells and TgCRND8 APP transgenic mice [33]. However, no significant changes in BACE1 protein levels were obtained in TgCRND8 APP transgenic mice when treated with baicalein. The Aβ increasing effect of baicalein might be due to its off-target action, probably via impairing ubiquitin proteasomal clearance function. These are significantly visible only while the administration of the compound is done in increased doses of 25 mg/kg/day. Zhang et al. [28] reported that Chinese hamster ovary cells expressing wild-type APP and Tg2576 mice, when treated with baicalein, showed reduced Aβ through promotion of the non-amyloidogenic pathway. This contrast in data might be due to the difference in incubation time. The data showing a decrease in the sAPPβ level is not shown in the study of Zhang et al. Hence, baicalein may modulate BACE1 in an extremely dose-dependent manner.

Camellikaempferoside B (4) is a natural acylglycoside flavone compound that is isolated from Fuzhuan brick tea [*fermented Camellia sinensis* (L.) Kuntze]. The structure of the compound contains groups of p-coumaric acid and rhamnopyranosyl along a kaempferol backbone. Yang et al. [34] showed that camellikaempferoside B (4) does not interfere with BACE1 expression, but it reduces BACE1 activity at a concentration of 25 µM in both a cell-free system and in APP-expressing cells. This compound acts on several of the active sites in BACE1 via hydrogen bonds, leading to a reduction in BACE1 activity and Aβ production. Preformed fibril disaggregation is shown by camellikaempferoside B (4), and this compound has also been shown to form structurally abnormal Aβ oligomers, which are not involved in pathogenesis [34].

Quercetin (5) is a flavonoid compound that is abundantly found in plants like *Allium cepa* L., *Malus pumila* Mill., etc. [35].

▶ Fig. 1 Schematic representation of βAPP processing and generation of Aβ peptides.
Shimmyo et al. [36] has shown that quercetin (5) reduces BACE1 activity in a cell-free system (IC₅₀ of 5.4 ± 0.5 µM). In a neuronal cell system, the compound has also showed BACE1 reducing activity (IC₅₀ of 50 µM). The compound appears to maintain its stability for about 24 h in vivo. Lu et al. [37] reported that quercetin-treated male C57BL/6 strain mice exhibited reduced BACE1 expression. Quercetin may reduce BACE1 expression and, thus, negatively regulate the amyloidogenic processing of βAPP. But the data provided does not show much significant reduction in BACE1 protein levels as claimed. Nevertheless, the abundance, stability, and wide availability of the compound and its action on the neuronal cell system provides a need for further studies.

Myricetin (6) is a plant-derived flavonoid compound that belongs to the class of polyphenols [38]. Due to its structural similarity to quercetin (5), myricetin (6) is sometimes referred to as hydroxyquercetin [29]. Since myricetin (6) has antioxidant properties, it has also been reported to show a neuroprotective effect against neuronal cell injury induced by Aβ [40]. The small molecular weight and hydrophobic characteristics may help it to cross the BBB, thus giving it a therapeutic advantage [41]. Shimmyo et al. [40] have reported that myricetin (6) has dual activity, as it can directly inhibit BACE1 activity without affecting protein expression and showed activation of a secretase (ADAM10) in a cell-free enzyme activity assay. The IC₅₀ of myricetin (6) was calculated to be 2.8 µM in inhibiting BACE1 activity. Three hydrogen bonds formed by myricetin (6) with BACE1 (one each with Gln 73 and Trp 198, and one with Asp32) stabilise the binding. The effect of myricetin (6) on neuronal cells is less than expected. Myricetin (6) has been shown to be unstable. This might be because, after 24 h of treatment, the compound is metabolised, losing the hydroxyl groups essential for BACE1 inhibition [40]. Myricetin (6) exhibits β-sheet structure disruption activity and also inhibits Aβ fibril generation [42].

Genistein (7) is an isoflavone compound isolated from Glycine max (L.) Merr., which inhibited BACE1 activity in a dose-dependent manner with an IC₅₀ value of 6.3 × 10⁻² M. It inhibits BACE1 activity in a noncompetitive irreversible manner. In vitro and cell-based studies, genistein (7) has also been shown to inhibit Aβ-induced inflammation and cell death [43–45]. Even at a higher concentration of 500 mg/kg/day in rats, it was found to be pharmacologically safe [46]. It was noted that even at a lower concentration, the compound was able to cross the BBB without causing any neurotoxicity [46]. The significance of the compound, to be considered as a potential candidate for AD treatment, requires further studies. The structure of flavonoids exhibiting potent anti-BACE1 activity is depicted in Fig. 2.

**Phenolics and Tannins Having Potential Anti-beta-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Activity**

Salvianolic acid B (8) (Sal B) was isolated from the root of Salvia miltiorrhiza Bunge (Lamiaceae family) [47]. This plant is widely used to treat cardiovascular and cerebrovascular diseases [48, 49]. Sal B (8) is a water-soluble polyphenolic caffeic acid derivative [50]. Lin et al. [51] showed that Sal B (8) can protect neuronal PC-12 cells from Aβ-induced toxicity. Further studies conducted by Durairajan et al. [52] reported that Sal B (8) can disaggagate preformed fibrils and inhibit Aβ fibril formation. Tang et al. and Durairajan et al. independently reported that Sal B modulated BACE1 activity in SH-SYSY-APPSw cells and it decreased Aβ generation in H4-SwedAPP, N2a-SwedAPP, and HEK-BACE1 cells. Many, possibly important, variations can be noticed in these studies: i) Tang et al. suggested that BACE1 expression was reduced at 50 µM [53], but Durairajan et al. [54] showed that Sal B (8) does not affect BACE1 expression. It only reduces BACE1 activity; ii) Tang et al. used a narrow range of concentrations (25–50 µM) of Sal B (8), whereas the other study used concentrations varying from 1–50 µM; iii) The higher concentrations of Sal B (8) may affect cellular viability, possibly leading to toxicity. Durairajan et al., in their studies, reported cellular toxicity and viability by the LDH and MTT analyses and found the range of concentrations to be safe. Tang et al. did not provide cellular viability results; iv) The decrease in the level of sAPPβ coincides with a decrease in CTFβ fragments. No data on CTFβ fragments was provided in the other study; and v) Durairajan et al. provided data of molecular docking and Sal B shows slight binding to the catalytic domain, whereas Tang et al. did not provide docking studies. Yu et al. [55] reported that Sal B shows negligible binding to the catalytic sites using molecular docking methods. Tang et al. suggest that Sal B suppresses BACE1 expression. But due to discrepancies between these results, further studies are required to clearly understand the mechanism of action of Sal B on BACE1 (Fig. 3).

Ferulic acid (9) is a phenolic compound that is included in the human diet, as it is found in cereals like Oryza sativa L. and Triticum aestivum L., in fruits like Solanum lycopersicum L., Ananas comosus (L.) Merr., and Citrus sinensis (L.) Osbeck, and in vegetables [56]. The compound is known to possess anti-inflammatory, anti-carcinogenic and antioxidant properties [57–59]. Mori et al. [56] reported that ferulic acid (9) acts by targeting BACE1, both in in vitro and in vivo studies conducted. At the concentration of 1.57 µM, this compound significantly reduced Aβ variants [57]. In a cell-free BACE1 activity assay, it was demonstrated that ferulic acid (9) acts on BACE1 by both directly attenuating BACE1 enzymatic activity and targeting BACE1 stability without affecting mRNA expression levels. Ferulic acid (9) has a low molecular weight (194.18 g/mol) [60], high bioavailability in rat models [57], and remains stable in the body, which serves as an advantage in therapeutics; however, due to its nature as a charged molecule with a hydroxyl group, its ability to cross the BBB remains uncertain [56]. Some reports have suggested the presence of the molecule in rodent brains following peripheral administration [60]. Hence, ferulic acid (9) and its derivatives have the potential to combat AD.

Tannic acid (10) is present in plants like Quercus velutina Lam., Camellia sinensis (L.) Kuntze, etc. Oral administration of tannic acid (10) improved behavioural impairment, reduced cerebral amyloidosis, and increased the anti-amyloidogenic βAPP processing in in vivo studies conducted in transgenic PSAPP mice (30 mg/kg/day dosage) without exhibiting any side effects [61]. Moreover, tannic acid has shown to dose-dependently downregulate the generation of Aβ40 and Aβ42 and inhibit the level of CTFβ cleavage products [61]. It was also noted that tannic acid inhibits BACE1 expression and β secretase activity without altering BACE1 mRNA, promoting

Naushad M et al. Natural Compounds with ... Planta Med 2019; 85: 1316–1325
non-amyloidogenic βAPP processing [61]. These properties increase the potential of tannic acid to progress into clinical studies. The structures of phenolics and tannins showing anti-BACE1 activity are depicted in ▶ Fig. 4.

Alkaloids Showing Inhibition of beta-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Activity

Berberine (11) is a multifunctional isoquinoline alkaloid with neuropharmacological properties, which can be isolated from plants like *Coptis chinensis* Franch., *Berberis vulgaris* L., and many more [62]. Asai et al. [63] showed that berberine modulated βAPP processing, resulting in a reduction of the Aβ protein. In our previous study, the chronic administration of berberine (11) in transgenic AD mice for approximately 4 months showed significant mitigation of Aβ pathology without influencing BACE1 protein levels at an oral dosage of 25 or 100 mg/kg per day [62]. *In vivo* studies have suggested that that berberine (11) is able to cross the BBB and reach the brain in a dose- and time-dependent manner [64]. It was reported that the berberine reduced BACE1 activity and prevented the neurodegeneration of the hippocampus in a rabbit model of AD [65]. Cai et al. [66] established that berberine inhibits β/γ-secretases (main components PS1, Aph-1α, and Pen-2) activity and enhances α-secretase, thereby alleviating Aβ pathology in the brains of AD transgenic mice. However, the BACE1 inhibitory activity of berberine (11) was found to be less (IC50 value > 100 µM) [67]. In another study, through surface plasmon resonance (SPR) binding analysis and docking studies, the direct binding of berberine and BACE-1 was illustrated [68]. Reports of berberine acting on the BACE1 expression levels are also available, hence, further studies are required for the identification of the potential mechanism of action of the compound [69]. No potential toxicity was shown by the compound in both the *in vivo* and *in vitro* studies conducted, but protoberberine alkaloids such as the epiberberine (12) groenlandicine (13) exhibit promising dose-dependent BACE1 noncompetitive inhibition with IC50 values of 8.55 and 19.68 µM, respectively [67]. Further evaluation of the protoberberine compounds can provide valuable insight on its mechanism of action. The structures of alkaloids having anti-BACE1 activity are depicted in ▶ Fig. 4.
Chalcones

2, 2′, 4′-Trihydroxychalcone acid (TDC) (14) from Glycyrrhiza glabra L. (licorice) (chalcones-flavanoids) noncompetitively inhibits BACE1 activity (Ki value of 3.08 µM). With an IC50 of 2.5 µM, TDC (14) showed a dose-dependent decrease in the generation of Aβ40 and Aβ42 levels in HEK293-APPswe cells by effectively suppressing BACE1 activity on the βAPP [70]. In the above cell-based assay and in vivo (B6C3-Tg mice) study, TDC (14) effectively decreased Aβ in cells by suppressing BACE1 activity without exhibiting any off-target effect on α and γ secretases and showed no effect on BACE1 protein levels. It ameliorated the neurobehavioural activities and memory impairment in an AD mouse model at a dosage of 9 mg/kg per day with no obvious animal toxicity [70].

Cardamonin (15), a chalconoid, isolated from Boesenbergia rotunda (L.) Mansf. has a strong inhibition value with an IC50 value of 4.35 ± 0.38 µM. The compound does not affect the TACE (α secretase) to cause any detrimental effects. The docking studies, with −9.5 kcal/mol results, suggest its affinity to tightly bind to the enzyme and it has been proved to easily pass the BBB [71]. The oral administration of cardamonin (15) for 30 weeks at the dose of 10 mg/kg did not exhibit any apparent toxicity, thus suggesting its safe consumption, but further tests such as in vitro, in vivo and cell viability should be done in order to justify the effectiveness of the compound [72]. Further confirmation of these results warrant the use of chalcones as therapeutic agents for AD. The structures of alkaloids and chalcones having anti-BACE1 activity are depicted in Fig. 5.

Terpenes

Gracilins are secondary metabolites that are derived from the marine sponge Spongionella Bowerbank. Leiros et al. [73] isolated several natural compounds from the marine sponge and conducted several in vivo and in vitro studies and found that gracilins can effectively reduce tau hyperphosphorylation and Aβ accumulation. Its successful action of Aβ reduction may be caused by its effective inhibition of the BACE1 enzyme. In SH-SYSY tau441 human cell lines and 3 xTg-AD mice studies, it was noted that gracilin L (16) at a mere concentration of 1 µM exhibited a significant BACE1 reduction, decreasing its activity by 24.6 ± 4.2% [74]. Even though the other gracilins obtained showed BACE1 inhibition activity, the % of decrease is comparatively not significant. Gracilin L (16) reduced the expression of tau levels by 48.2 ± 8.5% at a concentration of 1 µM. The levels of Aβ accumulation found in vivo after treatment with 0.04 mg/kg of gracilin L (16) showed an 86.2% decrease. The multitarget mechanism of action of the gracilin compound on various targets led to ERK inhibition, and BACE1 inhibition correlated with the action of reduced tau hyperphosphorylation. A decrease of Aβ highlights the value of the natural com-
pound to be used for targeting AD. The neuroprotective action reported earlier by Leirós et al. [74] was further cemented by the current data. Further studies might be required in order to lament the priority and viability of usage of this compound for AD treatment.

Ginsenosides, the major pharmacologically active compounds isolated from various species of ginseng like Panax ginseng C.A. Mey., have also been observed to reduce BACE1, albeit with a different mode of action. Ginsenosides are steroidal triterpenoid saponins with a four-ring steroid backbone. Chen et al. [75] reported that three ginsenosides [Re (17), Rg1 (18) or Rg3 (19)] at a dose of 25 mg/kg significantly reduced the amount of Aβ40/ Aβ42 conducted in a cellular-based assay in Tg2576 mice. Ji et al. [76], in the same year, reported that ginsenoside Re (17) protects PC12 cells from cellular injury induced by amyloid Aβ. Ginsenosides Re (17) was observed to reduce BACE1 activity along with BACE1 expression, having no effect on the total APP levels and sAPPα levels in in vitro studies [77]. Ginsenoside Rg1 (18) showed improved memory and learning capacity in in vitro studies conducted. Wang et al. [78] reported that ginsenoside Rg1 (18) downregulated BACE1 activity and protects against Aβ-induced cytotoxicity in in vitro studies conducted in PC12 cells. The IC50 value of Rg1 was 6.18 ± 0.96 µM.

Asperterpenes A and B (20 and 21), meroterpenoids obtained from the soil-derived mold Aspergillus terreus Thom., have shown potent BACE1 inhibitory activities in a cell-based assay using HEK-BACE1 cells. The IC50 values of the asperterpenes A and B (19 and 20), obtained were 78 and 59 nM, respectively. When HEK-293 and N2a-APP cell lines were treated with asperterpene A (20) at a concentration of 70 nM, it significantly reduced Aβ42 formation and inhibited BACE1 activity. In animal studies conducted on triple transgenic mice (3XTgAD mice), asperterpene A (21) treatment ameliorated learning and memory deficit along with BACE1 activity (concentration 2 µg/µL). The exposure of the cells to this compound did not affect cell viability or cause toxic effects in the in vivo and in vitro studies conducted [79]. Qi et al. [80] isolated new meroterpenoids, asperterpenes from Aspergillus terreus, cultured on Oryza sativa L. Of the 10 isolated compounds, asperterpenes E, F, and J exhibited better BACE1 inhibitory activities compared to others, with IC50 values of 3.32, 5.85, and 31.68 µM, respectively, in a BACE1 FRET (fluorescence resonance energy transfer) inhibition experiment. Terreusterpenes A and B, which are compounds isolated from extracts of A. terreus, displayed potential BACE1 inhibitory activity in in vitro studies (IC50 values of 5.98 and 11.42 µM) [81]. Compounds isolated from A. terreus, up till now, have displayed one of the strongest inhib-
ions against BACE1 activity and reduction in the formation of Aβ. These findings thus warrant the use of asperterpenes as an anti-AD therapeutic agent. The structures of terpenes and terpenoids showing anti-BACE1 activity are depicted in Fig. 6.

Conclusion and Future Perspectives

The potential of BACE1 to act as a therapeutic target in the treatment of AD has only been investigated for the past decade. Evidence suggests that the timing of administration of BACE1 inhibitors may play a critical role in the successful treatment of AD. The advancement in future diagnostic technologies will lead to the identification of high-risk individuals easier and, hence, provide potential for early treatment [82]. The side effects related to BACE1 inhibition are of some concern, but the novel method of βAPP-selective BACE inhibition reduces the risks. The identification and characterisation of natural BACE1 inhibitors have potential in anti-AD therapeutics, as the long-term use of these compounds in different ancient treatments also provides an advantage of its safety profile. All natural products discussed in this review article have the ability to effectively inhibit BACE1 activity and lower neurotoxic Aβ formation. Focussing on the effects of the natural compounds on their action as anti-AD therapeutic agents brings focus to their mechanistic view of action by specifically targeting BACE1 substrate without any off-target action. In the future, we may discover more natural compounds showing severe efficiency, specificity, bioavailability, and safety with an effective grip on the various novel mechanisms of action to efficiently treat AD.

Acknowledgements

This work was supported by grants from Hong Kong’s Health and Medical Research Fund (HMRF 15163481) and the Department of Science and Technology’s Core Research grant (SERB/CRG/2018/001596), Government of India. The authors also thank Dr. Martha Dahlen for her English editing and critical review.

Conflict of Interest

The authors declare that they have no conflict of interest.

References


[38] Semwal DK, Semwal RB, Combrinck S, Viljoen A. Myricetin: A dietary molecule with diverse biological activities. Nutrients 2016; 8: 90


[59] Sultana R, Ravagna A, Mohammed-Ahmed H, Calabrese V, Butterfield DA. Ferulic acid ethyl ester protects neurons against amyloid β-peptide (1–


[71] Youn K, Jun M. Biological evaluation and docking analysis of potent BACE1 inhibitors from Boesenbergia rotundata. Nutrients 2019; 11: 662


[76] Chen F, Eckman EA, Eckman CB. Reductions in levels of the Alzheimer’s amyloid beta peptide after oral administration of ginsenosides. FASEB J 2006; 20: 1269–1271


